ArticleBMC infectious diseases2026
Epidemiological characteristics and risk factors associated with bacteremia caused by intrinsically colistin-resistant gram-negative microorganisms: a case-control study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors and clinical characteristics of bacteremia caused by intrinsically colistin-resistant Gram-negative microorganisms (ICRMs) in intensive care unit (ICU) patients and to compare them with Klebsiella pneumoniae bacteremia.
methodsThis retrospective case-control study was conducted in the ICUs of a tertiary-care hospital in Türkiye between January 2023 and February 2024. Adult patients with ICRM-positive blood cultures were compared with those with colistin-susceptible or colistin-resistant Klebsiella pneumoniae bacteremia, and demographic, clinical, and outcome data were analyzed.
resultsIn total, 439 patients were included: 148 with ICRM bacteremia, 191 with colistin-susceptible K. pneumoniae bacteremia, and 100 with colistin-resistant K. pneumoniae bacteremia. Exposure to colistin or polymyxin B within the previous three months was independently associated with ICRM bacteremia (OR = 2.87, 95% CI = 1.29-6.39, p = 0.010). Polymicrobial bacteremia was identified in 20% of ICRM cases (30/148), most commonly involving Enterococcus spp. (7/30). New-onset BSIs within fourteen days of the initial bacteremia were more frequent in the ICRM group (16.9%, 25/148) than in both K. pneumoniae groups (p < 0.05), with K. pneumoniae as the most common pathogen (40%, 10/25). ICRM bacteremia cases were more often community-acquired or healthcare-associated and were associated with lower Sequential Organ Failure Assessment (SOFA) scores and mortality rates than both K. pneumoniae groups (each p < 0.05).
conclusionICRM bacteremia poses a growing threat in critically ill patients due to intrinsic and increasing acquired resistance. Prior colistin or polymyxin-B exposure was identified as an independent risk factor, and these infections were more often polymicrobial and community- or healthcare-associated than K. pneumoniae bacteremia. Given the limited ICU-focused evidence on ICRM bacteremia, these findings highlight prior polymyxin exposure as a potentially modifiable risk factor and support antimicrobial stewardship efforts. Therefore, empirical therapy in high-risk patients should consider potential ICRM involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.